Sumant ramachandra biography of rory
Home / Celebrity Biographies / Sumant ramachandra biography of rory
Fixed Compensation
| Component | Policy Terms | FY2024 Actual (Ramachandra) |
|---|---|---|
| Annual Board cash retainer | $50,000 for non-employee directors (Lead Independent: $80,000; Board Chair: $85,000) | $8,709 (pro‑rated for Oct–Dec 2024; appointed to committee in Dec 2024) |
| Committee member fee | Audit $10,000; Compensation $7,500; Nominating & Governance $5,000 (chair fees: $20,000/$15,000/$10,000 respectively) | Included in pro‑rated FY2024 cash fees (member, Nominating & Governance) |
Performance Compensation
| Equity Vehicle | Grant Date | Shares Granted | Grant-Date Fair Value ($) | Vesting | Change-of-Control Treatment |
|---|---|---|---|---|---|
| Non-employee director stock option (initial appointment) | Oct 31, 2024 | 260,000 | 168,558 | 36 equal monthly installments from appointment date, contingent on continued service | All outstanding director equity awards fully vest immediately prior to closing of a Change in Control, subject to continuous service |
| Annual non-employee director option (structure) | Annual meeting each year | Lesser of Black-Scholes $300,000 or 130,000 shares | Policy-defined | Vests fully at next annual meeting or first anniversary, subject to service | Same as above |
Notes:
- Director equity uses options; no PSUs/RSUs or performance metrics are used for director compensation under the policy.
Expertise & Qualifications
- Medical and scientific credentials (M.D., Ph.D.), oncology and cell therapy experience; senior R&D and operating leadership at Baxter/Pfizer/Hospira/Merck; MBA (Wharton). To see all exchange delays and terms of use please see disclaimer.
- Attendance: Board met 8 times in FY2024; all current directors except Mr.
Nelsen attended at least 75% of aggregate Board/committee meetings; executive sessions held regularly. Before joining Hospira in July of 2008, he held various research and development roles at Merck, Pharmacia, Pfizer and Schering-Plough, developing and winning FDA approval of many different live-saving treatments, particularly in the cancer area.
Governance Assessment
- Strengths: Independent director with deep biotech R&D and operating experience; adds transaction/integration insight post-ImmPACT acquisition; member of Nominating & Governance overseeing governance/ESG/compliance; attendance threshold met. Press the link below or the continue button to keep going.ContinueCancel
Get a Dose of ReachMD in Your Inbox and Practice Smarter Medicine
Stay current with the best on medical education
.
(Rutgers), and MBA (Wharton).As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Continued monitoring is prudent around any ImmPACT-linked transactions and committee deliberations to ensure ongoing robust independence safeguards.
He also later earned a master's of business administration at Wharton Business School.
Recommended
Press cancel to remain on ReachMD.
Equity Ownership
| Metric | Value |
|---|---|
| Total beneficial ownership (shares) | 243,333 (includes 200,000 held by the Sumant Ramachandra Revocable Trust and 43,333 options exercisable within 60 days of March 31, 2025) |
| Ownership as % of outstanding | <1% (asterisk per table) |
| Options held (total) | 260,000 (initial appointment grant) |
| Insider policy – pledging/hedging | Directors prohibited from hedging, pledging, short sales, derivatives; margin purchase banned.
Ramachandra has nearly two decades of healthcare experience.
|